|
| Overall Recruitment Status: Active, currently enrolling |
| |
| Official Title |
| A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) |
| |
| Region |
Sponsors |
| California - Northern |
|
| |
| Acronym |
NCT No. |
|
NCT05882877 |
| |
| Study Type |
Phase |
| Clinical Trial |
|
| |
| Purpose |
| The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD. |
| |
| Detailed Description |
|
| |
| |
| |
- • Completion of an end of treatment duration visit (Week 24 or Week 52 visit for adult or adolescent studies, respectively) in a rocatinlimab parent study (ROCKET-IGNITE, ROCKET-HORIZON, ROCKET-SHUTTLE, ROCKET-ASTRO, ROCKET-ORBIT, OR ROCKET-VOYAGER) within the past 28 days.
|
|
| |
- • Permanent investigational product discontinuation due to safety-related reasons, protocol-defined stopping rules or conditions/reasons unrelated to efficacy during the rocatinlimab parent study (ROCKET-IGNITE, ROCKET-HORIZON, ROCKET-SHUTTLE, ROCKET-ASTRO, ROCKET-ORBIT, OR ROCKET-VOYAGER), or at the time of Screening or Day 1.
|
|
| |
- Atopic Dermatitis, Rocatinlimab, AMG 451, Eczema,
|
|
|
|
|
|
|
|
|
| |
|